$INDP

Indaptus Therapeutics, Inc. has reported a net loss of $2.54 million for Q1 2026 and an accumulated deficit of $83.83 million, leading to a substantial doubt about its ability to continue as a going concern. The company's stockholders' equity decreased significantly, and it anticipates needing additional capital beyond Q2 2026, which will likely result in dilution for existing shareholders. Investors are warned of high market volatility and the potential for complete loss of investment given the company's clinical-stage status and limited operating history.